We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Review · February 15, 2021

Effect of GLP1-Receptor Agonists or SGLT2 Inhibitors Without Metformin on CV Outcomes

Diabetic Medicine: A Journal of the British Diabetic Association

 

Additional Info

Diabetic Medicine: A Journal of the British Diabetic Association
SGLT2 Inhibitors and GLP1 Agonists Administered Without Metformin Compared to Other Glucose-Lowering Drugs in Patients With Type 2 Diabetes Mellitus to Prevent Cardiovascular Events: A Systematic Review
Diabet. Med. 2020 Dec 23;[EPub Ahead of Print], C Escobar, V Barrios, J Cosín, JM Gámez Martínez, AI Huelmos Rodrigo, C Ortíz Cortés, J Torres Llergo, C Requeijo, I Solà, MJ Martínez Zapata

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading